Advertisement


Myriam Chalabi, MD, PhD, on Colon Cancer: New Findings on Neoadjuvant Immune Checkpoint Inhibition

ESMO Congress 2022

Advertisement

Myriam Chalabi, MD, PhD, of The Netherlands Cancer Institute, discusses data from the NICHE-2 study, which confirms previously reported pathologic responses to short-term neoadjuvant nivolumab plus ipilimumab in patients with locally advanced mismatch repair–deficient colon cancer. Survival data suggest neoadjuvant immunotherapy may become standard of care and allow further exploration of organ-sparing approaches. (Abstract LBA7).



Related Videos

Lung Cancer
Immunotherapy

Martin Reck, MD, PhD, on NSCLC: New Findings on Cemiplimab, Nivolumab, and Ipilimumab

Martin Reck, MD, PhD, of Germany’s Lung Clinic Grosshansdorf, details two trials that included patients with advanced non–small cell lung cancer: 3-year survival outcomes in the EMPOWER-Lung 1 study of continued cemiplimab-rwlc beyond disease progression with the addition of chemotherapy, and phase III results from the IFCT-1701 trial of nivolumab plus ipilimumab 6-month treatment vs treatment continuation (LBA54 and Abstract 972O).

Skin Cancer
Immunotherapy

Georgina V. Long, MD, PhD, on Melanoma: Findings on Circulating Tumor DNA, Disease Recurrence, and Immunotherapy

Georgina V. Long, MD, PhD, of the Melanoma Institute Australia, discusses results from the CheckMate 915 trial, an analysis of the pretreatment circulating tumor DNA, along with other clinical and translational baseline factors, and their association with disease recurrence in patients with stage IIIB–D/IV melanoma treated with adjuvant immunotherapy (Abstract 788O).

Kidney Cancer

Nizar M. Tannir, MD, on RCC: Data on Bempegaldesleukin Plus Nivolumab vs Tyrosine Kinase Inhibitors in Untreated Disease

Nizar M. Tannir, MD, of The University of Texas MD Anderson Cancer Center, discusses phase III findings from the PIVOT-09 study, which compared bempegaldesleukin plus nivolumab with the investigator’s choice of a tyrosine kinase inhibitor (either sunitinib or cabozantinib) in patients with previously untreated advanced renal cell carcinoma (Abstract LBA68).

Gynecologic Cancers

Paul A. DiSilvestro, MD, on Ovarian Cancer: New Data on Olaparib in Newly Diagnosed Disease

Paul A. DiSilvestro, MD, of Women & Infants Hospital and the Warren Alpert Medical School of Brown University, discusses overall survival results after a 7-year follow-up of the SOLO1/GOG-3004 trial for patients with newly diagnosed advanced ovarian cancer and a BRCA mutation who received maintenance olaparib. Dr. DiSilvestro details the increasing role of such PARP inhibitors in ovarian cancer treatment and their benefit to patients (Abstract 517O).

Breast Cancer

Matthew P. Goetz, MD, on Breast Cancer: Interim Survival Results With Abemaciclib Plus a Nonsteroidal Aromatase Inhibitor

Matthew P. Goetz, MD, of Mayo Clinic, discusses recent data from the MONARCH 3 trial of patients with advanced hormone receptor–positive, HER2-negative breast cancer. The study, a second interim analysis, showed that longer overall survival was observed in both the intention-to-treat group as well as in the subgroup with visceral disease. However, neither met the threshold for statistical significance, and further analyses are planned when more data can be reported. (Abstract LBA15).

Advertisement

Advertisement




Advertisement